

Controversies in Muscle Invasive Bladder Cancer: What Do We Not Know But Want to Know?

Sam S. Chang, MD

Patricia and Rodes Hart Professor of Urologic Surgery
Vanderbilt University Medical Center

MIBC: Surgical Controversies

- Neobladder versus conduit urinary diversion
- Robotic versus Open cystectomy
 - Efficacy with non-inferior
 - Cost concerns
 - Intracorporeal versus extracorporeal
- Ideal ERAS
- Is there ever a role for partial cystectomy; Should everyone/anyone consider Bladder-sparing regimens?

Tan WS et al, BJU Intl, 2018

Collins W et al, Eur Urol, 2016

Tyson M and Chang SS, Eur Urology, 2016

Parekh D et al, Lancet, June 2018

MIBC: Surgical Controversies

- Should radical cystectomies or treatment for invasive bladder cancer only be done at centers of excellence?
- What factors affect outcomes other than patient morbidity?
- Nutritional / immunonutrition interventions PRIOR to cystectomy

Odisho AY, et al, Cancer, 2018
Scarberry K et al Urol Oncol, 2018
Smith AB et al, Urol Oncol, 2018
Xia L, et al, Urology, 2018
Ryan S, et al, J Urol, 2018
Holzbeierlein, J Urol, 2017

MIBC: Clinical Considerations at TURBT

- Complete or maximal TURBT for invasive disease
 - Should repeat resection be performed prior to neoadjuvant therapy?
 - What about if there is cT0 disease at resection?
- Role of improved techniques for TURBT
 - En bloc resection
 - Other techniques or combination with improved endoscopic imaging
- Current trials evaluating primary tumor evaluation after neoadjuvant chemotherapy—what is current practice?

Kukreja JB, et al Eur Urol Focus, 2017
Kramer MW, et al, Eur Urol Focus, 2017

MIBC: Variant Histology

- Variant Histology
 - Variant histology—neoadjuvant treatment recommended and/or discussed?
 - Does percentage of type of variant make a difference?
 - In small cell cancer patients who receive neoadjuvant systemic therapy, is localized treatment necessary?

Ku JH, Bladder Cancer, 2018
Chang SS, J Urol, 2017

MIBC: Imaging

- MRI is the best axial imaging: Yes or No?
 - Localized imaging to determine depth of invasion
 - Nodal evaluation
- What is role of PET imaging?

Expert Panel, JACR, 2018

Hermans TJN, et al, Urol Oncol, 2017

Teo MY and Rosenberg JE, Urol Clin N America, 2018

Panebianco V, et al, Eur Urol, 2018

MIBC: Predictive Markers

- Role of genomic classification and molecular subtypes
 - Prognostic
 - Predictive
- PD-1 / PD-L1 expression
- Serum or urine biomarkers—any helpful in invasive disease?

Tetracoral M, Mod Pathol, 2018

Pichler R, et al, Clin Genito Cancer, 2018

Seiler R, et al, Eur Urol, 2017

Seiler R, et al, J Urol, 2016

Expert Panel, JACR, 2018

Hermans TJN, et al, Urol Oncol, 2017

Teo MY and Rosenberg JE, Urol Clin N America, 2018

Panebianco V, et al, Eur Urol, 2018

MIBC: Metastatic Disease

- Nodal/Metastatic that responds to systemic therapy: What Next—observe, operate, radiate, or all of the above?
- Extended lymph node dissection: Is it Really Necessary? If so, what are the boundaries?
- What to do with N+ disease post-cystectomy? Should adjuvant treatment always be given, and if so—what and when?
- What about XRT role?

Abufaraj M et al, Eur Urol, 2018

Li R et al, Bladder Cancer, 2018

Shah S, et al, Clin Genit CA, 2017

MIBC: Systemic Therapy

- Immunotherapy
 - Neoadjuvant
 - AUA/ASCO abstract: pembro x 3
 - ASCO abstract: atezo x 2
 - Adjuvant?
 - What is sequence or best choice?
 - Neoadjuvant combination therapy?
 - The use of PD-1 / PD-L1 expression: Is it required and if so, in what situation and what tests?
 - Which of the current FDA-approved agents should be used: in what setting, in what order, in which patients?

Trotta M, Mod Pathol, 2018

Pichler R, et al, Clin Genito Cancer, 2018

Expert Panel, JACR, 2018

Hermans TJN, et al, Urol Oncol, 2017

Teo MY and Rosenberg JE, Urol Clin N America, 2018

Panebianco V, et al, Eur Urol, 2018